Work

Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw383.78

Authors: A. Gajra, H. Ali, K.I. Amiri, N. Abdel Karim, M.R. Matrana, D. Mulford, T.J. Ong, A. Sanford, E. Santos, M. Socinski, D.R. Spigel, R.C. Lilenbaum

Institutions: SUNY Upstate Medical University, Henry Ford Hospital, Celgene (United States), University of Cincinnati, Ochsner Medical Center, University of Rochester Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, Sarah Cannon, Yale Cancer Center, Yale University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587823842

FWCI: 0.299

Cites:

Cited by: 1

Related to: 10